Search

Your search keyword '"Beeker, Aart"' showing total 7 results
Start Over Author "Beeker, Aart" Publisher wiley
7 results on '"Beeker, Aart"'

2. HOVON110/ReBeL Study: Results of the Phase I Part of a Randomized Phase I/II Study of Lenalidomide, Rituximab With or Without Bendamustine in Patients With Relapsed/Refractory Follicular Lymphoma

Author

Stevens, Wendy B.C., primary, Bakunina, Katerina, additional, Cuijpers, Marloes, additional, Chamuleau, Martine, additional, Beeker, Aart, additional, Fijnheer, Rob, additional, Hebart, Holger, additional, Visser, Hein P.J., additional, Doorduijn, Jeanette K., additional, Linton, Kim, additional, Dreyling, Martin, additional, de Jong, Daphne, additional, and Kersten, Marie José, additional

Published
2020
Full Text
View/download PDF

3. Bevacizumab combined with docetaxel, oxaliplatin, and capecitabine, followed by maintenance with capecitabine and bevacizumab, as first-line treatment of patients with advanced HER2-negative gastric cancer: A multicenter phase 2 study

Author

Meulendijks, Didier, De Groot, Jan Willem B, Los, Maartje, Boers, James E., Beerepoot, Laurens V., Polee, Marco B., Beeker, Aart, Portielje, Johanna E A, Goey, Swan H., De Jong, Robert S., Vanhoutvin, Steven A L W, Kuiper, Maria, Sikorska, Karolina, Pluim, Dick, Beijnen, Jos H., Schellens, Jan H M, Grootscholten, Cecile, Tesselaar, Margot E T, Cats, Annemieke, Sub Clinical Pharmacology, and Pharmacoepidemiology and Clinical Pharmacology

Subjects
Adult, Male, 0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, Organoplatinum Compounds, Bevacizumab, Receptor, ErbB-2, Phases of clinical research, Antineoplastic Agents, Docetaxel, Neutropenia, Drug Administration Schedule, Capecitabine, 03 medical and health sciences, 0302 clinical medicine, Leukocytopenia, Stomach Neoplasms, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Humans, Medicine, Prospective Studies, Methylenetetrahydrofolate Reductase (NADPH2), Aged, business.industry, gastric cancer, clinical trial, Middle Aged, Neoplastic Cells, Circulating, medicine.disease, Oxaliplatin, Regimen, 030104 developmental biology, phase 2, 030220 oncology & carcinogenesis, Female, Taxoids, business, medicine.drug
Abstract

The current study was a multicenter, single-arm, phase 2 study performed to investigate the feasibility and efficacy of bevacizumab combined with docetaxel, oxaliplatin, and capecitabine (B-DOC) in patients with advanced human epidermal growth factor receptor 2 (HER2)-negative, previously untreated, gastric or gastroesophageal adenocarcinoma.Tumor HER2 status was determined centrally. Patients received 6 cycles of bevacizumab at a dose of 7.5 mg/kg, docetaxel at a dose of 50 mg/m(2) , and oxaliplatin at a dose of 100 mg/m(2) (all on day 1) combined with capecitabine at a dose of 850 mg/m(2) twice daily (days 1-14) every 3 weeks followed by maintenance with capecitabine and bevacizumab in patients with disease control. The primary objective was to demonstrate a progression-free survival (PFS) of6.5 months, according to the 95% confidence interval (95% CI). Secondary endpoints included safety, objective response rate, overall survival (OS), analyses of circulating tumor cells (CTCs), and pharmacogenetic analyses.Sixty eligible patients were enrolled. The median PFS was 8.3 months (95% CI, 7.2-10.9 months). The objective response rate was 70% (95% CI, 55%-83%) and the disease control rate was 96% (95% CI, 85%-99%). The median OS was 12.0 months (95% CI, 10.2-16.1 months). According to CTC-AE v4.0, the most common treatment-related grade ≥3 adverse events were neutropenia (20%), leukocytopenia (18%), diarrhea (15%), and nausea/vomiting (15%). The presence of CTCs at baseline was strongly predictive of PFS (hazard ratio [HR], 3.8; P =.007) and OS (HR, 3.4; P =.014). The methylenetetrahydrofolate reductase (MTHFR) 677CT genotype was strongly associated with PFS (HR, 4.7 for TT vs CC or CT; P =.0007) and OS (HR, 5.9; P =.0001).The B-DOC regimen plus maintenance was feasible and active. CTCs were found to be prognostic in patients treated with B-DOC. Docetaxel-based triplet chemotherapy as a backbone for targeted therapies is feasible and deserves further study. Cancer 2016;122:1434-1443. © 2016 American Cancer Society.

Published
2016

4. Treatment strategies for polycythemia vera: Observations in a Dutch “real‐world” cohort study

Author

van de Ree‐Pellikaan, Claire, primary, de Kreuk, Arne, additional, Schaar, Cees G., additional, Beeker, Aart, additional, Dompeling, Ellen C., additional, Gerrits, Cees J. H., additional, Houten, Anja A., additional, Schipperus, Martin R., additional, Strobbe, Leonie, additional, Posthuma, Eduardus F. M., additional, Klauke, Karin, additional, and Westerweel, Peter E., additional

Published
2019
Full Text
View/download PDF

5. AR splice variants in circulating tumor cells of patients with castration‐resistant prostate cancer: relation with outcome to cabazitaxel

Author

Sieuwerts, Anieta M., primary, Onstenk, Wendy, additional, Kraan, Jaco, additional, Beaufort, Corine M., additional, Van, Mai, additional, De Laere, Bram, additional, Dirix, Luc Y., additional, Hamberg, Paul, additional, Beeker, Aart, additional, Meulenbeld, Hielke J., additional, Creemers, Geert‐Jan, additional, Weerden, Wytske M., additional, Jenster, Guido W., additional, Nieuweboer, Annemieke J. M., additional, Mathijssen, Ron H. J., additional, Wit, Ronald, additional, Martens, John W. M., additional, and Sleijfer, Stefan, additional

Published
2019
Full Text
View/download PDF

6. First-line treatment selection and early monitoring patterns in chronic phase-chronic myeloid leukemia in routine clinical practice: SIMPLICITY

Author

Goldberg, Stuart L., primary, Cortes, Jorge E., additional, Gambacorti-Passerini, Carlo, additional, Hehlmann, Rüdiger, additional, Khoury, H. Jean, additional, Michallet, Mauricette, additional, Paquette, Ron L., additional, Simonsson, Bengt, additional, Zyczynski, Teresa, additional, Foreman, Aimee, additional, Abruzzese, Elisabetta, additional, Andorsky, David, additional, Beeker, Aart, additional, Cony-Makhoul, Pascale, additional, Hansen, Richard, additional, Lomaia, Elza, additional, Olavarria, Eduardo, additional, and Mauro, Michael J., additional

Published
2017
Full Text
View/download PDF

7. Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named p

Author

van der Helm, Lieke H., primary, Alhan, Canan, additional, Wijermans, Pierre W., additional, van Marwijk Kooy, Marinus, additional, Schaafsma, Ron, additional, Biemond, Bart J., additional, Beeker, Aart, additional, Hoogendoorn, Mels, additional, van Rees, Bastiaan P., additional, de Weerdt, Okke, additional, Wegman, Jurgen, additional, Libourel, Ward J., additional, Luykx-de Bakker, Sylvia A., additional, Minnema, Monique C., additional, Brouwer, Rolf E., additional, Croon-de Boer, Fransien, additional, Eefting, Matthijs, additional, Jie, Kon-Siong G., additional, van de Loosdrecht, Arjan A., additional, Koedam, Jan, additional, Veeger, Nic J. G. M, additional, Vellenga, Edo, additional, and Huls, Gerwin, additional

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results